On May 14, 2025, Needham analyst Mike Matson reiterated his Buy rating on Lucid Diagnostics (LUCD, Financial). The analyst maintains the price target at USD 3.00, keeping it unchanged from the prior assessment.
The decision to reaffirm the Buy rating and the stable price target suggests continued confidence in Lucid Diagnostics' market performance despite no change in the price target figures this time.
Lucid Diagnostics (LUCD, Financial) continues to be viewed positively by Needham's research team, as indicated by the maintained Buy rating. As the price target remains steady at USD 3.00, it underscores a consistent outlook for the company's stock potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Lucid Diagnostics Inc (LUCD, Financial) is $3.75 with a high estimate of $7.50 and a low estimate of $2.00. The average target implies an upside of 207.38% from the current price of $1.22. More detailed estimate data can be found on the Lucid Diagnostics Inc (LUCD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lucid Diagnostics Inc's (LUCD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lucid Diagnostics Inc (LUCD, Financial) in one year is $8.84, suggesting a upside of 624.59% from the current price of $1.22. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lucid Diagnostics Inc (LUCD) Summary page.
